a lil' dap'll do ya

sharon jonesThis is one of those shows where you’re simply not supposed to ask why.

Never heard of Sharon Jones? Don’t worry. You’ll love her. Not big on vintage soul music? Well, you should be. But the finger-popping, brass-happy, twang-hearty Dap Kings that have long served as Jones’ backup band will have you forgetting about labels, tags and genres. What this crew comes up with is R&B, blues and roots-inspired party music that bears an unavoidable retro slant and a huge contemporarary heart.

With three extraordinary indie albums to her credit, soul diva Jones is finally heading to Kentucky. She performs with the Dap Kings on Friday at Headliners Music Hall in Louisville.

The Georgia born, Brooklyn bred Jones’ newest album with the Dap Kings, 2007’s sublime 100 Days, 100 Nights , fortifies her sense of soul smarts with a vocal command that leans heavily on gospel. No surprise there. Jones started singing in church choirs. She shows off that inspiration directly with help from bluesman Alvin Youngblood Hart and the Carolina Chocolate Drops on the dynamite soundtrack to The Great Debaters.

Now here is the crowning touch. You need to hit the road to Louisville early enough to hear the show-opening Ivan Milev band. Accordionist Milev has been a prime ambassador of Balkan and Bulgarian folk music for over three decades. While he resides in New York, his band still consists exclusively of Eastern European players. Among them is Milev’s apprentice, violinist Entcho Todorov. Together they create positively mad and boundlessly enthusiastic acoustic music. It’s a soul sound from, literally, another world. Check out these samples.

Louisville’s DJ Kim Sorise, co-host of the city’s famed Dirty Soul Party public radio program, will also be on hand. So Scrap whatever plans you have for tonight. You need to be at this show. It’s just that simple.

(above photo of Sharon Jones by Dulce Pinzon)

Sharon Jones and the Dap Kings, The Ivan Milev Band and DJ Kim Sorise perform at Headliners Music Hall, 1386 Lexington Rd. in Louisville on Friday. Showtime is 9 p.m. Tickets are $12. Call (502) 584-8088.

Study data from University of Texas, M. D. Anderson Cancer Center update knowledge of mantle cell lymphoma immunology. site mantle cell lymphoma

Health & Medicine Week May 26, 2008 Researchers detail in ‘A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma,’ new data in mantle cell lymphoma. In this recently published study, investigators in the United States conducted a study “To establish a severe combined immunodeficient (SCID)-hu in vivo mouse model of human primary mantle cell lymphoma (MCL) for the study of the biology and novel therapy of human MCL. Primary MCL cells were isolated from spleen, lymph node, bone marrow aspirates, or peripheral blood of six different patients and injected respectively into human bone chips, which had been s.c. implanted in SCID-hu.” “Circulating human beta(2)-microglobulin in mouse serum was used to monitor the engraftment and growth of patient’s MCL cells. H & E staining and immunohistochemical staining with anti-human CD20 and cyclin D1 antibodies were used to confirm the tumor growth and migration. Increasing levels of circulating human beta(2)-microglobulin in mouse serum indicated that the patient’s MCL cells were engrafted successfully into human bone chip of SCID-hu mice. The engraftment and growth of patient’s MCL cells were dependent on human bone marrow microenvironment. Immunohistochemical staining with anti-human CD20 and cyclin D1 antibodies confirmed that patient’s MCL cells were able to not only survive and propagate in the bone marrow microenvironment of the human fetal bone chips, but also similar to the human disease, migrate to lymph nodes, spleen, bone marrow, and gastrointestinal tract of host mice. Treatment of MCL-bearing SCID-hu mice with atiprimod, a novel antitumor compound against the protection of bone marrow stromal cells, induced tumor regression,” wrote M. Wang and colleagues, University of Texas, M. D. Anderson Cancer Center (see also Mantle Cell Lymphoma Immunology). here mantle cell lymphoma

The researchers concluded: “This is the first human primary MCL animal model that should be useful for the biological and therapeutic research on MCL.” Wang and colleagues published their study in Clinical Cancer Research (A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clinical Cancer Research, 2008;14(7):2154-60).

For additional information, contact M. Wang, The University of Texas M D Anderson Cancer Center, The University of Texas M D Anderson Cancer Center, Division of Cancer Medicine, Houston, Texas 77030 USA..

The publisher of the journal Clinical Cancer Research can be contacted at: American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA.



Comments are closed.


Terms of Service | Privacy Policy | About Our Ads | Copyright